Temmune Therapeutics: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Temmune Therapeutics
Largest movements
- Cash +€925,661
up €925,661 (+172%), from €538,138 to €1.5m
mainly Contributions, distributions and other (+€2.0m) and Depreciation (+€1.9m)
- Intangible fixed assets -€150,472
down €150,472 (-8.0%), from €1.9m to €1.7m
- Receivables after one year +€58,651
up €58,651 (+42.3%), from €138,539 to €197,190
- Deferred charges and accrued income -€51,430
down €51,430 (-96.5%), from €53,272 to €1,841
- Profit (loss) carried forward -€1.6m
down €1.6m (-209%), from -€756,243 to -€2.3m
- Contributions +€1.4m
up €1.4m (+45.8%), from €3.0m to €4.3m
of which Capital: +€1.4m
- Debts after one year +€1.1m
up €1.1m, from €0 to €1.1m
- Trade debts -€103,391
down €103,391 (-24.4%), from €423,615 to €320,224
- Depreciation +€969,815
up €969,815 (+106%), from €918,469 to €1.9m
- Purchases and services +€879,663
up €879,663 (+74.1%), from €1.2m to €2.1m
- Taxes +€79,888
up €79,888 (+57.7%), from -€138,539 to -€58,651
- Gross operating margin -€54,870
down €54,870 (-17.0%), from -€322,150 to -€377,020
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €2,647,972 | €3,434,090 | +€786,118 | +29.7% |
| Fixed assets | 21/28 | €1,886,995 | €1,736,522 | -€150,472 | -8.0% |
| Intangible fixed assets | 21 | €1,886,995 | €1,736,522 | -€150,472 | -8.0% |
| Current assets | 29/58 | €760,978 | €1,697,567 | +€936,590 | +123% |
| Amounts receivable after more than one year | 29 | €138,539 | €197,190 | +€58,651 | +42.3% |
| Other amounts receivable | 291 | €138,539 | €197,190 | +€58,651 | +42.3% |
| Amounts receivable within one year | 40/41 | €31,029 | €34,737 | +€3,708 | +12.0% |
| Trade receivables | 40 | €0 | - | = | |
| Other amounts receivable | 41 | €31,029 | €34,737 | +€3,708 | +12.0% |
| Cash at bank and in hand | 54/58 | €538,138 | €1,463,799 | +€925,661 | +172% |
| Deferred charges and accrued income | 490/1 | €53,272 | €1,841 | -€51,430 | -96.5% |
| Total equity and liabilities | 10/49 | €2,647,972 | €3,434,090 | +€786,118 | +29.7% |
| Equity | 10/15 | €2,224,357 | €2,013,866 | -€210,492 | -9.5% |
| Contributions | 10/11 | €2,980,601 | €4,347,048 | +€1.4m | +45.8% |
| Capital | 10 | €2,980,601 | €4,347,048 | +€1.4m | +45.8% |
| Issued capital | 100 | €2,980,601 | €4,347,048 | +€1.4m | +45.8% |
| Contributions outside capital | 11 | €0 | - | = | |
| Other | 1109/19 | €0 | - | = | |
| Profit (loss) carried forward | 14 | -€756,243 | -€2,333,182 | -€1.6m | -209% |
| Amounts payable | 17/49 | €423,615 | €1,420,224 | +€996,609 | +235% |
| Amounts payable after more than one year | 17 | €0 | €1,100,000 | +€1.1m | |
| Financial debts | 170/4 | €0 | €1,100,000 | +€1.1m | |
| Amounts payable within one year | 42/48 | €423,615 | €320,224 | -€103,391 | -24.4% |
| Trade debts | 44 | €423,615 | €320,224 | -€103,391 | -24.4% |
| Suppliers | 440/4 | €423,615 | €320,224 | -€103,391 | -24.4% |
| Goods, raw materials, services and sundry goods | 60/61 | €1,187,614 | €2,067,277 | +€879,663 | +74.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €918,469 | €1,888,284 | +€969,815 | +106% |
| Other operating charges | 640/8 | €1,038 | €670 | -€368 | -35.5% |
| Gross operating margin | 9900 | -€322,150 | -€377,020 | -€54,870 | -17.0% |
| Operating profit (loss) | 9901 | -€1,241,657 | -€2,265,973 | -€1.0m | -82.5% |
| Financial income | 75/76B | €4,742 | €4,069 | -€673 | -14.2% |
| Recurring financial income | 75 | €4,742 | €4,069 | -€673 | -14.2% |
| Financial charges | 65/66B | €9,289 | €7,239 | -€2,050 | -22.1% |
| Recurring financial charges | 65 | €9,289 | €7,239 | -€2,050 | -22.1% |
| Profit (loss) for the period before taxes | 9903 | -€1,246,204 | -€2,269,144 | -€1.0m | -82.1% |
| Income taxes | 67/77 | -€138,539 | -€58,651 | +€79,888 | +57.7% |
| Profit (loss) for the period | 9904 | -€1,107,665 | -€2,210,492 | -€1.1m | -99.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€1,107,665 | -€2,210,492 | -€1.1m | -99.6% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 26 October 2026 via checked.be.